Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 94 citing articles:

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma, John J.V. McMurray
Diabetologia (2018) Vol. 61, Iss. 10, pp. 2108-2117
Open Access | Times Cited: 792
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Gary D. Lopaschuk, Subodh Verma
JACC Basic to Translational Science (2020) Vol. 5, Iss. 6, pp. 632-644
Open Access | Times Cited: 618
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
Fabrice Bonnet, André Scheen
Diabetes & Metabolism (2018) Vol. 44, Iss. 6, pp. 457-464
Closed Access | Times Cited: 261
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
Milton Packer, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 10, pp. 1270-1278
Open Access | Times Cited: 251
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
Stefan D. Anker, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 10, pp. 1279-1287
Open Access | Times Cited: 223
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Hsiang‐Chun Lee, Yi-Lin Shiou, Shih‐Jie Jhuo, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 169
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 149
Adiponectin, Leptin and Cardiovascular Disorders
Shangang Zhao, Christine M. Kusminski, Philipp E. Scherer
Circulation Research (2021) Vol. 128, Iss. 1, pp. 136-149
Open Access | Times Cited: 140
Role of Leptin in Cardiovascular Diseases
Mareike S. Poetsch, Anna Strano, Kaomei Guan
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 137
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease
Milton Packer, Carolyn S.P. Lam, Lars H. Lund, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 9, pp. 1551-1567
Open Access | Times Cited: 128
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology
Petar Seferović, Gabriele Fragasso, Mark C. Petrie, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 9, pp. 1495-1503
Open Access | Times Cited: 122
The effects of sodium‐glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions
N. Lan, P. Gerry Fegan, Bu B. Yeap, et al.
ESC Heart Failure (2019) Vol. 6, Iss. 5, pp. 927-935
Open Access | Times Cited: 87
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes
Milton Packer
JACC Heart Failure (2021) Vol. 9, Iss. 8, pp. 535-549
Open Access | Times Cited: 78
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
Giuseppe Palmiero, Arturo Cesaro, Erica Vetrano, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5863-5863
Open Access | Times Cited: 77
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, et al.
Current Heart Failure Reports (2021) Vol. 18, Iss. 5, pp. 315-328
Open Access | Times Cited: 76
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease
Hongyan Liu, Vikas S. Sridhar, Jacinthe Boulet, et al.
Metabolism (2021) Vol. 126, pp. 154918-154918
Closed Access | Times Cited: 63
SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF ‐2α signaling pathway in arrhythmogenic cardiomyopathy
Zhe Yang, Tengling Li, Jianzhong Xian, et al.
The FASEB Journal (2022) Vol. 36, Iss. 7
Open Access | Times Cited: 52
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 37
Adipokines and Cardiometabolic Heart Failure with Preserved Ejection Fraction: A State-of-the-Art Review
Nikolaos Theodorakis, Magdalini Kreouzi, Christos Hitas, et al.
Diagnostics (2024) Vol. 14, Iss. 23, pp. 2677-2677
Open Access | Times Cited: 12
Hypoxia‐inducible factor 1‐alpha (HIF‐1α) as a factor mediating the relationship between obesity and heart failure with preserved ejection fraction
Ian Warbrick, Simon W. Rabkin
Obesity Reviews (2019) Vol. 20, Iss. 5, pp. 701-712
Closed Access | Times Cited: 74
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
Subodh Verma
The American Journal of Cardiology (2019) Vol. 124, pp. S36-S44
Open Access | Times Cited: 74
What does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition
Jessica A. Dominguez, Timo Rieg
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. S2, pp. 43-52
Open Access | Times Cited: 66
Metabolism of the failing heart and the impact of SGLT2 inhibitors
Álvaro García‐Ropero, Carlos G. Santos‐Gallego, M. Urooj Zafar, et al.
Expert Opinion on Drug Metabolism & Toxicology (2019) Vol. 15, Iss. 4, pp. 275-285
Closed Access | Times Cited: 59
Biomarkers in Heart Failure with Preserved Ejection Fraction
Antoni Bayés‐Genís, Germán Cediel, Mar Domingo, et al.
Cardiac failure review (2022) Vol. 8
Open Access | Times Cited: 34
Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases
Alaaeldin Bashier, Azza Bin Hussain, Elamin Abdelgadir, et al.
Diabetology & Metabolic Syndrome (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 52
Page 1 - Next Page

Scroll to top